Katja Evert

TL;DR: It is reported that melanoma patients with high expression of glycolysis-related genes show a worse progression free survival upon anti-PD1 treatment, and this findings support the rationale for targeting Glycolytic tumors together with checkpoint inhibitors in clinical trials.

TL;DR: In this paper, a comprehensive analysis of pancreatic autopsy tissue from COVID-19 patients using immunofluorescence, immunohistochemistry, RNA scope and electron microscopy was performed and detected SARS-CoV-2 viral infiltration of beta-cells in all patients.

TL;DR: This study suggests that mTOR kinase inhibitors may be beneficial for the treatment of ICC, even in tumors that are resistant to standard of care chemotherapeutics, especially in the subset of tumors exhibiting activated AKT/mTOR cascade.

TL;DR: This study indicates the functional contribution of mTORC2/Akt1 along c‐Myc‐induced hepatocarcinogenesis, with AKT1 and AKT2 having distinct roles in HCC development and progression; targeting both m TORC1 and mTorC2 may be required for effective treatment of human HCC displaying c‐ myc amplification or overexpression.

TL;DR: Evidence is provided that glycolytic tumor types can be independent of the organ of origin, prognostically relevant and might help select the appropriate immunotherapy approach.